Cita APA

Slingluff, C. L., Zarour, H. M., Tawbi, H. A., Kirkwood, J. M., Postow, M. A., Friedlander, P., . . . Wolchok, J. D. (2021). A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology.

Citación estilo Chicago

Slingluff, Craig L., et al. "A Phase 1 Study of NY-ESO-1 Vaccine + Anti-CTLA4 Antibody Ipilimumab (IPI) in Patients With Unresectable or Metastatic Melanoma." Oncoimmunology 2021.

Cita MLA

Slingluff, Craig L., et al. "A Phase 1 Study of NY-ESO-1 Vaccine + Anti-CTLA4 Antibody Ipilimumab (IPI) in Patients With Unresectable or Metastatic Melanoma." Oncoimmunology 2021.